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Summary 
CD44 is a cell surface adhesion molecule that plays a role in leukocyte extravasation, leukopoiesis, 
T  lymphocyte activation, and tumor metastasis.  The principal known ligand for CD44 is the 
glycosaminoglycan hyaluronate,  (HA),  a  major constituent  of extracellular matrices.  CD44 
expression is required but is not sufficient to confer cellular adhesion to HA, suggesting that 
the adhesion function of the receptor is regulated. We recently demonstrated that CD44 in primary 
leukocytes is phosphorylated in a cell type- and activation state-dependent fashion. In this study 
we demonstrate that serines 325 and 327 within the cytoplasmic domain of CD44 are required 
for the constitutive phosphorylation of CD44 in T cells. Furthermore, we demonstrate that ceils 
expressing mutated CD44 containing a serine to glycine substitution at position 325 or a serine 
to alanine substitution at amino acid 327 are defective in HA binding, CD44-mediated adhesion 
of T  cells to  smooth muscle cells,  as well as ligand-induced receptor modulation.  The effect 
of these mutations can be partially reversed by a monoclonal anti-CD44 antibody that enhances 
CD44-mediated HA binding. 
C 
D44 is a type I transmembrane glycoprotein expressed 
on leukocytes, some nonleukocytes, and many tumor 
cells.  CD44 is a receptor for hyaluronate (HA)  1, which is 
found ubiquitously as a constituent of extracellular matrices. 
Increased levels of HA are often associated with inflamma- 
tion and malignancies (1-5).  Although many CD44 + cell 
lines and tumors exhibit CD44-mediated HA binding, normal 
CD44 + leukocytes do not bind HA  appreciably in vitro. 
The expression of CD44 is upregulated 10-fold on lympho- 
cytes after antigen receptor-mediated activation (6, 7); how- 
ever, this enhanced CD44 expression does not necessarily lead 
to the induction of HA binding in the majority of lympho- 
blasts.  We have described cell type- and activation state- 
dependent variations in the N-linked glycosylation, the phos- 
phorylation, and the cytoskeletal association of CD44 (8). 
Furthermore, Lesley et al.  (9) demonstrated that the cyto- 
plasmic domain of CD44 is required for optimal HA binding 
function. These authors also described a mAb, IRAWB14.1, 
that is specific for CD44. This mAb enhanced CD44-mediated 
HA binding by cell lines and normal CD44 § leukocytes that 
show little, if any, basal affinity for HA (9,  10). This mAb 
also overcame the HA binding defect of a cytoplasmic tail 
1 Abbreviations used in  this paper: ASM, airway smooth muscle; HA, 
hyaluronate. 
minus truncation mutant (9). In this study, we addressed the 
possibility that phosphorylation of the cytoplasmic domain 
of CD44 in leukocytes is at least in part responsible for the 
regulated adhesion function of CD44. 
Materials and Methods 
Antibodies.  Three monodonal anti-routine CD44 mAbs were 
used in these studies. The KM201 mAb directed against the HA 
binding domain was generously  provided  by Dr. ~ul Kincade (Okla- 
homa Medical Research Foundation, Oklahoma City, OK) (11). 
IKAWB14.1, an anti-CD44  which enhances HA binding,  was 
provided by Drs. Jayne Lesley and Robert Hyman (Sulk Institute, 
La Jolla, CA) (9). IM7 was obtained from Dr. Ian Trowbridge (Salk 
Institute)  (12). Hybridomas  producing  anti-CD44  mAbs were 
grown in serum-free medium, mAbs were partially purified from 
crude superuatants by precipitation in 50% saturating ammonium 
sulfate. 
CD44  Constructs and  Transfectants.  A  full-length,  1,388-bp 
cDNA done, rlcp1, encoding the 363-amino acid hematopoietic 
form of CD44, was isolated by immunosdection from a murine 
anti-Ig activated B cell cDNA library constructed in pCDM8 (ob- 
tained from Dr. Brian Seed, Cambridge, MA) and expressed in 
COS-7 cells. The truncation mutant, CD44A1011, was generated 
by subdoning the HindlII-PstI  fragment  of rlcpl  (amino acid 
residues 1-338) into pRc/CMV (Invitrogen, San Diego, CA). Point 
mutants containing a Ser --~ Gly substitution  at residue 325 and 
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two-step PCR amplification  with complementary primers  con- 
taining an A ~  G mutation at nucleotide 973 and a T ~  G muta- 
tion at nucleotide 979, respectively. The resulting mutants were 
sequenced  to verify the presence of the mutations as well as the 
fidelity of the PCK, and subcloned  into pRc/CMV. The parental 
AKK1.G10 thymoma line was transfected by electroporation with 
40 #g of purified  plasmid  DNA. Stable  subclones  were isolated 
by two rounds ofimmunoselection with IM7 using anti-rat Ig-con- 
jugated magnetic beads (Dynal, Oslo, Norway) and two rounds 
ofimmunoselection for high expression as detected by FITC-KM201 
and fluorescence-activated  cell sorting followed by limiting dilu- 
tion cloning. The stable AKK1.G10 transfectants  expressing  wild 
type and the cytoplasmic tail minus mutant encoding residues 1-297 
were obtained from Drs. Lesley and Hyman (9). All clones were 
subcloned  and selected based on similar  levels of expression. 
Immunoprecipitation  and Phosphoamino  Acid Analysis  of CD44. 
Thymoma cells were incubated for 1 h in phosphate-free  KPMI 
supplemented with 5% dialyzed FCS and then loaded with 2 mCi 
ortho-nphosphate for 3.5 h (~9,000 Ci/mM; New England Nu- 
clear, Boston, MA). After labeling,  cells were washed  and lysed 
in  PBS  containing  1%  NP-40,  protease  inhibitors  (0.2  U/ml 
aprotinin, 1 mM PMSF, and 100 #g/ml leupeptin;  Sigma Chem- 
ical  Co.,  St.  Louis,  MO),  and phosphatase inhibitors  (50  mM 
NaH2PO4, 50 mM KF, and 10 mM sodium pyrophosphate;  Sigma 
Chemical Co.). Lysates were clarified by centrifugation at 10,000 g 
at 4~  for 10 rain and the NP-40 soluble fraction was precleared 
with normal rat Ig and mouse anti-rat Ig conjugated to Sepharose. 
Lysates were reacted with rat anti-mouse CD44 mAb, IM7, and 
the immune complexes precipitated with Sepharose-mouse anti-rat 
Ig. Precipitates were washed with high salt (0.6 M NaC1, 125 mM 
KPO4, pH 7.4, and 0.02% NAN3), mixed detergent  buffer (0.05% 
NP-40, 0.1% SDS, 0.3 M  NaC1, and 10 mM Tris, pH 8.6),  and 
PBS. Immune complexes were then eluted by boiling in 2 x Laemmli 
running buffer containing 0.4% dithiothreitol and electrophoresed 
on 7% polyacrylamide  gels. Molecular weight standards were oh- 
A 
,~cyt 
AIOll  [ 
Extracellular  Cytoplasmic  Domain 
k/X/"  \\  ~:  r  ==  = 
5 'U.T.  \\  S293  S318  S325 S327  $339 
I 
S356  3'U.T. 
B  aa269PEWLIILASLLALALILAVCIAV-N~ 
nt  805  CCAGAA~GGCTCATCATCTTGGCATCTCTCCTGGCACTGGCTCTGATTCTTGCCGTCTGCATCGCGGTCAATAGT 
Acyt  ........................................................................... 
AI011  ........................................................................... 
325  ........................................................................... 
327  ........................................................................... 
293s325t327  ........................................................................  G-- 
aa294RRRCGQKKKLVINGGNGTVEDRKPS 
nt  880  AGGAGAAGGTGTGGGCAGAAGAAAAAGCTGGTGATCAACGGTGGCAATGGGACAGTGGAAGACAGGAAACCCAGT 
Acyt  ............ 3' 
A1011  ........................................................................... 
325  ........................................................................... 
Figure  1.  Expression of wild- 
type CD44 and CD44 mutants on 
stable transfectants of AKR1.G10 
thymoma  cells. (A) Schematic  of  the 
primary structure of CD44. Poten- 
tial sites of serine phosphorylation 
327  ........................................................................... 
293,325,327  ...........................................................................  within the cytoplasmic domain are 
aa  319  E  L  N  G  E  A  S  K  ~  Q  E  M  V  H  L  V  N  K  E  P  S  E  T  P  D  indicated.  Serines are indicated by 
nt  955  GAGCTCAACGGGGAGGCCAGCAAGTCTCAGG,~KATGGTGCATTTGGTGA~CAAGG-~a~CCATCAGAGACCCCAGAC  circle  (potential protein kinase C 
~c~,t  target), triangle (potential cAMP- 
1011  ............................................................  3,  dependent protein kinase target), or 
325  ..................  G  -  ........................................................  327  ........................  _~  ..................................................  squares  (not a known kinase target 
293,325,327  ..................  G .....  G ..................................................  consensus sequence). Nucleotide 
aa344QCMTADETRNLQSVDMKIGV 
nt  1030  CAGTGTATGACAGCTGACGAGACCCGGAATCTGCAGAGTGTGGACATG~GATTGGGGTG-3' 
Acyt 
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designations are based on the initi- 
ation start codon being 1. (B) Se- 
quence of the cytoplasmic  domains 
of  the wild-type and mutant CD44 
constructs. The potential sites of 
serine phosphorylation  are indicated 
by boldface type. (C) Flow cytom- 
etry of AKR1.G10 thymoma cells 
transfected  with  vector  alone 
(pRc/CMV, solid line), wild-type 
CD44 construct (WT, dotted line), 
and in the left panel with A1011 
(dashed line) or Acyt (boldface solid 
line) (9), or the construct containing 
the  point  mutations,  serine 325 
(boldface dashed line). In the right 
panel, staining of cells transfected 
with  CD44 with  the  serine 327 
point mutation is depicted by the 
boldface dashed line. 
56  Point Mutations in CD44 Affect Phosphorylation and Adhesion tained from Bio-Rad Laboratories (Melville, NY). Gels were dried 
and exposed to film for 24 h. For phosphoamino acid analysis, bands 
corresponding to CD44 were cut out from the dried gels, reswollen 
in 2.5% acetic acid/10% methanol, and dehydrated in 50% meth- 
anol. The gel slice was dried by vacuum desiccation, and rehydrated 
in 50 mM ammonium bicarbonate, digested with 0.1 mg/ml ther- 
molysin (Boehringer Mannheim, Indianapolis, IN) at 370C for 12 
h; the ehted peptide fragments were dried by vacuum desiccation. 
Lyophilized peptides were acid hydrolyzed in 6 M HC1 at 100~ 
for  2 h in  vacuo, relyophilized,  and resuspended in  8%  acetic 
acid/2% formic acid, pH 1.9. The sample was then resolved on 
a cellulose TLC plate (Eastman Kodak, Rochester, NY) in parallel 
with 2 #g each of unlabeled phosphoserine, phosphothreonine, and 
phosphotyrosine  standards. The plate was electrophoresed at 400 
V for 60 rain first at pH 1.9 followed by pH 3.5 for 30 rain. The 
TLC plate was dried,  stained with 1%  ninhydrin in acetone to 
visualize the standards, and subjected to phosphorimage  analysis 
and fluorography. 
HA Binding and Adhesion Assays.  Hyaluronic acid and hyaluroni- 
dase were purchased from Sigma Chemical Co. HA was conjugated 
to fluorescein by the method of deBelder and Wik (13). Cells were 
reacted with FITC-HA for 45 rain on ice and analyzed on a flow 
cytometer  (Coulter  Corp.,  Hialeah,  FL). 
To assay for binding  to insoluble HA, transfected AKR1.G10 
cells were radiolabeled by overnight culture in medium containing 
2 #Ci/ml [3H]thymidine (NET027X,  New England Nuclear) and 
then washed to remove free [3H]tbymidine. 10  s cells in 100 #1 were 
added to 96-well microtest plates precoated with 100 #1 of 50 #g/ml 
HA in PBS. After 1 h, nonadherent cells were removed by washing. 
Adherent cells were quantitated  by lysing in 0.5% Triton X-100 
and counting. 
Where indicated, cells were pretreated with either the blocking 
anti-CD44 mAb, KM201, for 45 min at 4~  or with the enhancing 
antibody, IRAWB14.1, for 15 rain at 4~  Sensitivity of adhesion 
to hyaluronidase was determined by adding hyaluronidase for 5 rain 
at 37~  at the end of the adhesion assay  before removing the nonad- 
herent cells. 
Lymphocyte Adhesion to Airway Smooth Muscle Cells.  Airway 
smooth muscle cells (ASM) were isolated as previously described 
(14). 8  x  10  s transfected AKR1.G10 cells radiolabeled as described 
above, were added to ASM cell monolayers in 24-well culture plates 
and incubated for I h at 4~  Where indicated, cells were pretreated 
with mAb as described above or with 100 #g/ml HA for 45 min 
at 4~  Sensitivity to hyaluronidase was determined as described 
above. 
Cell Surface Modulation of CD44.  AKR..G10 transfectants were 
suspended at 107 in cold media containing 10% FCS. 106 cells were 
reacted with 10 #g/ml of IRAWB14.1 anti-CD44  at either 4 or 
37~  After 45 min, unbound mAb was removed by washing and 
the ceils were stained with a FITC-conjugated,  mouse anti-rat  Ig 
at 4~  Excess secondary antibody was removed by washing and 
the cells were fixed in 3.7% formaldehyde/PBS. Samples were ana- 
lyzed under oil on a Leitz fluorescence  microscope  and photographed 
on ASA 400 Kodachrome film at a magnification  of 1,000. 
Results 
Serines 325 and 327 Are Required for the Constitutive Phos- 
phorylation of CD44 in T Cells.  The cytoplasmic domain of 
murine  CD44 contains  10 potential phosphorylation  sites: 
6 serines and 4 threonines (Figs.  1, A and B). Phosphoamino 
acid analysis  of wild-type recombinant  CD44 expressed in 
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AKR1.G10 cells demonstrated that  CD44 is constitutively 
phosphorylated on one or more serine residue(s) (Fig.  2 A). 
Neither phosphothreonine nor phosphotyrosine was detected. 
To map the site(s) of constitutive phosphorylation in T cells, 
we established stably transfected cell lines expressing similar 
levels  of wild-type  or  mutant  forms  of CD44  using  a 
CD44-  T  cell line,  AKR1.G10  (Fig.  1, B  and  C).  These 
mutants encode amino acid substitutions that remove poten- 
tial sites of serine phosphorylation within the CD44 intra- 
ceUular domain of a cDNA clone, rlcpl,  of murine  CD44 
(Fig. 1 B). Serines 293 and 325 were replaced by glycine residues 
and serine 327 with an alanine residue. There were comparable 
levels of expression of CD44 on each of the transfected lines 
in comparison to staining  of cells transfected with vector alone 
as detected by a FITC-conjugated anti-CD44 mAb and ana- 
lyzed by flow cytometry (Fig.  1 C). Treatment with the en- 
hancing  anti-CD44  mAb,  IRAWB14.1,  did not effect the 
level of CD44 expressed by any of the transfected lines (data 
not  shown). 
Phosphorylation  of the receptor in each transfected line 
was investigated  by immune  precipitation  of CD44  from 
detergent  lysates of ortho-32phosphate-labeled  cells.  Phos- 
phorylated  CD44  precipitated  from cells  expressing wild- 
type recombinant CD44 has an apparent molecular mass of 
~90 kD (Fig.  2, B and C, middle lane). The Acyt mutation, 
which retains  only serine 293 of the cytoplasmic tail,  was 
not phosphorylated (Fig. 2 B). Similarly, mutants that con- 
tained either a single substitution  at  serines  325 or 327 or 
three substitutions  at serines 293,  325,  and 327,  were not 
phosphorylated (Fig. 2 C). These results are consistent with 
those recently reported for CD44 expressed in epithelial ceils 
(15). 
T  Cells Expressing Nonphosphorylated Forms of CD44 Do 
Not Adhere to HA.  Lesley et al.  (9) demonstrated that the 
CD44-  parental  AKK1.G10  cell  line  does  not  bind  ap- 
preciably to soluble or insoluble HA. Expression  of wild- 
type recombinant  CD44 confers upon the AKK1.G10 line 
the capacity to bind to either form of HA (Fig.  3, A  and 
B; 9).  In contrast,  the line expressing a truncated  form of 
CD44 lacking all but the first six residues of the cytoplasmic 
domain bound soluble HA poorly, although the binding was 
dramatically enhanced by treating the cells with IRAWB14.1 
(9). This result is illustrated in Fig. 3. Cells transfected with 
vector without insert  did not bind HA in the presence or 
absence of IRAWB14.1 (Fig.  3 A). These results indicated 
that the cytoplasmic domain is required for the optimal adhe- 
sion function  of the extracellular  domain  of CD44. 
We analyzed the HA binding of cells transfected with the 
Ser325  ~  Gly and Ser327 ~  Ala mutants of CD44 to ad- 
dress the possibility that phosphorylation of the cytoplasmic 
domain is required for the adhesion function of the extracel- 
lular domain.  We compared the capacity of the aforemen- 
tioned transfected cell lines expressing wild-type and mutant 
forms of CD44 to bind  soluble FITC-HA (Fig.  3 A)  and 
to adhere to immobilized HA (Fig.  3 B). Cells expressing 
the nonphosphorylated mutants of CD44 bound soluble HA 
minimally (Fig.  3 A, top) and did not mediate adhesion to 
HA-coated surfaces (Fig. 3 B). In contrast, the mutant A1011 which retains approximately half of the cytoplasmic domain 
including serines 325 and 327, binds HA at levels similar to 
wild type (Fig.  3 C, and data not shown), indicating that 
the NH2-terminal half of the cytoplasmic tail is sufficient to 
confer HA binding function. 
We have recently developed a more physiologic assay for 
CD44  adhesion function in which we quantitate CD44- 
HA-mediated adhesion of T  cells to ASM cell monolayers 
(16). We demonstrated that activated human T cells adhere 
to human ASM via integrins and CD44 (16). We also ex- 
ploited the fact that routine LFA-1 does not bind to human 
intercellular adhesion molecule 1 (17) whereas CD44-mediated 
binding is not species specific (18) to demonstrate that CD44 
is suffident to mediate T  cell adhesion to ASM (16). Thus, 
the CD44-  murine thymoma cells, AKR.G10, did not ad- 
here to human ASM whereas AKtL.G10 cells transfected with 
a wild-type construct of routine CD44 did. A comparison 
of adhesion of the various transfectants in this assay demon- 
strates  that serines 325  (Fig.  4) and 327 (data  not shown) 
are  required  for  CD44-HA-mediated  T  cell  adhesion  to 
smooth muscle cell monolayers. 
The defect in CD44 adhesion function of all the nonphos- 
phorylated mutants, i.e., Acyt, 325, 327, and 293/325/327, 
could be in large part be reversed by treating the cells with 
the anti-CD44 mAb IRAWB14.1 (Fig. 3 A, middle, Fig. 3, 
B, and C, and Fig. 4). Both constitutive and mAb-induced 
HA binding in all three assays were inhibited by the blocking 
anti-CD44 mAb KM201 (Fig. 3 A,  bottom, and Fig. 4) or 
by an excess of soluble HA (Fig. 3 B and Fig. 4). In addition, 
HA binding could be reversed by subsequent digestion with 
hyaluronidase  (Fig.  3,  B and C  and Fig.  4). 
Ligand.induced Modulation of CD44  Is Defective in  Non- 
phosphorylated Mutants.  We compared the distribution of 
wild-type and mutant CD44 on the cell surface and the sus- 
ceptibility of wild-type and mutant receptors to ligand-induced 
modulation using fluorescence microscopy. Transfectants ex- 
pressing wild-type, Acyt, or serines 327 (Fig. 5, top) or 325 
(data not shown) reacted with FITC-anti-CD44 at 4~  all 
exhibited similar staining in ring patterns typical of cell sur- 
face proteins that are evenly distributed on the membrane. 
In contrast, the distribution of the wild-type and mutant forms 
of CD44 were markedly different  when the cells were in- 
cubated with anti-CD44 antibodies and detected with a sec- 
ondary FITC-anti-rat Ig (Fig. 5) or treated with the enhancing 
anti-CD44 mAb, IRAWB14, and FITC-HA (data not shown) 
at 37~  for 1 h. Ligand binding at 37~  resulted in limited 
clustering of wild-type CD44 that was evident as patches 
of fluorescence over the entire surface of the cells (Fig.  5, 
bottom left). In contrast, ligand binding induced a more rad- 
ical modulation  of CD44 in the mutations, Acyt (Fig. 5, bottom 
Figure 2.  Serines  325 and 327 are required for the constitutive phosphor- 
ylation of CD44 in T cells. AKK1.G10 cells expressing the recombinant 
forms of CD44 described in Fig. 1 were loaded with ortho-32phosphate. 
NP-40 lysates were prepared and CD44 was immunoprecipitated  with 
the mAb IM7 and subsequently resolved on a 7% SDS-polyacrylamide 
gel (B and C). A phosphoamino  acid analysis of 32P-labeled  CD44 from 
AKR1.G10 transfected with the wild-type CD44 construct is shown (A). 
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Figure 3.  T cells expressing the nonphosphorylated mutants of CD44 
do not bind HA. AKR1.G10 transfected with pRc/CMV (solid line), wild- 
type CD44 (CD44wt3b, stippled line), CD44 Ser325 --~ Gly (boldface dashed 
line), and CD44 Ser327 ~  Ala (boldface solid line) were determined to ex- 
press similar levels of the respective recombinant proteins by staining with 
FITC-KM201 (see Fig. 1) and then analyzed for their capacity to bind 
to HA. (A) Flow cytometric analysis of soluble FITC-HA binding. Un- 
treated (top) or IRAWB14.1 induced (center) AKR1.G10 transfectants were 
reacted with FITC-HA in the absence (top and center) or presence (bottom) 
of 10 #g/m1 of the blocking anti-CD44 mAb KM201  and analyzed by 
flow cytometry. (B and C) Insoluble HA binding: AKR1.G10 cells trans- 
fected with the indicated constructs were loaded with [3H]thymidine and 
adhered  to wells of microtiter plates coated with 50 #g/ml HA, in the 
presence of 10 #g/ml normal rat Ig (solid bars), 10 #g/ml IRAWB14.1 
(hatched bars), 10 #g/ml KM201 (shaded bars), 100 #g/m1 soluble HA (open 
bars), or digested after adhesion with 200 #g/m1 hyaluronidase (crosshatched 
bars). Data are expressed as a percentage of input cells bound. 
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center),  serines 327 (Fig.  5, bottom  right) and 325  (data not 
shown). Ligand binding to each of the mutant forms of CD44 
resulted in the accumulation of the receptor into a single polar 
cap on the vast majority of the cells. 
Discussion 
In this study we describe two point mutations in the cyto- 
plasmic domain of CD44 that result in the loss of phosphory- 
lation of the receptor as well as its affinity for HA compared 
with wild-type CD44. These mutants provide definitive evi- 
dence that point mutations in the cytoplasmic domain of an 
adhesion receptor can severely limit the function of the ex- 
tracellular domain of the receptor. We conclude from this 
study that  the potential for phosphorylation of CD44  on 
serines 325 and/or 327 is required for optimal CD44-mediated 
HA binding in T cells. This is the first direct evidence that 
the regulation of the adhesion function of this receptor is 
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Figure  4.  Serine  325 is required for CD44/HA-mediated adhesion of 
T cell adhesion to ASM cells. ASM monolayers  in 24-well culture dishes 
were established as previously  described  (14). Transfected  AKR.G10 cells 
were radiolabeled  and treated with normal rat Ig (solid bars), IRAWB14.1 
(hatched bar), KM201 (shaded bar), or 100 #g/ml HA (open bars). 
related to its potential to be phosphorylated.  This may re- 
flect a requirement for the phosphate group(s) per se or the 
negative charge that it would provide.  The latter has been 
suggested,  for example,  as an explanation for the defect in 
the transcytosis of the poly Ig receptor with a serine to ala- 
nine mutation  since substitution  of the relevant serine res- 
idue with an aspartic acid residue does not result in defective 
transcytosis  (19). 
Although  HA is the principal  defined ligand  for CD44 
in vitro, adhesion in vivo involves HA in the context of como 
plex extracellular matrices.  An example of a distinction be- 
tween receptor-mediated ligand recognition and adhesion to 
a physiologic substrate was recently published.  Kansas et al. 
(20) demonstrated that deletion of the COOH-terminal  11- 
amino acids from the 17-amino acid cytoplasmic domain of 
L-selectin  eliminated  binding  of lymphocytes  to  high  en- 
dothelial venules in the in vitro frozen section assay.  It also 
abolished leukocyte rolling in vivo in exteriorized rat mesen- 
teric venules, but this mutation did not alter the lectin reac- 
tivity of L-selectin.  In this case, pretreatment of cells with 
cytochalasin B also abolished adhesion without affecting car- 
bohydrate recognition. Therefore, it was important to evaluate 
the effect of the serine 325  and 327 mutations  on binding 
to HA in a more physiologically relevant assay.  The move- 
ment of lymphocytes into tissues involves a cascade of adhe- 
sion receptor-mediated interactions with the endothelium that 
has in large part been delineated. Despite the importance of 
the endothelium in regulating tissue infiltration by lympho- 
cytes, other cells such as fibroblasts or vascular or tissue smooth 
muscle cells which are a major source of HA may also play 
a role. We recently found that  activated T  cells can adhere 
to ASM cells in vitro (16).  This assay was used to evaluate 
the effect on HA-mediated adhesion of AKR1.G10 cells ex- 
Figure  5.  Defective  ligand-induced redistribution  of mutant forms of  CD44 on the cell surface. Basal distribution of CD44 on the surface  of  AKR.G10 
cells expressing wild-type (left)  and the tail minus (center) and Ser327---Ala  mutants of CD44 was determined by staining with IRAWB14 followed 
by FITC-mouse anti-rat Ig at 4~  (top).  Receptor modulation was induced by incubating the cells in the presence  of IRAWB14 at 37~  for 45 min 
and then stained with FITC-mouse anti-rat  Ig (bottom). 
60  Point Mutations in CD44 Affect Phosphorylation and Adhesion pressing the nonphosphorylated mutants of CD44. The ca- 
pacity of the various transfectants to adhere to smooth muscle 
cells directly correlated with their capacity to bind HA. 
There are several  possible mechanisms by which the muta- 
tions in the cytoplasmic domain of CD44 may affect the func- 
tion of the extracellular domain. They could result in a change 
in the conformation of the receptor, interfere with the normal 
distribution or ligand-induced redistribution of the receptor 
or change its association with other cellular proteins.  Any 
of these phenomena may be regulated by the state of phos- 
phorylation of the receptor. Although we have not ruled out 
the possibility of an effect on the conformation of the receptor, 
it is worth noting that the mutant receptors are reactive with 
each of a panel of four mAbs to distinct epitopes of the ex- 
tracellular domain (data not shown) and HA binding of the 
mutant receptor can be restored by mAb-induced receptor 
cross-linking, suggesting that the mutants can take on a func- 
tional conformation. The fact that the adhesion function of 
CD44 can be upregulated by treatment with an antireceptor 
mAb suggested that either dustering of the receptor or a 
conformational change in the receptor is required for optimal 
HA binding (21). The requirement for bivalent binding of 
the mAb for activation of HA binding (21) suggests that the 
distribution of the CD44 on the cell surface is critical to the 
HA adhesion function of the receptor. We demonstrate that 
the pattern of ligand-induced  modulation of the wild-type 
and mutants forms of CD44 are distinct.  Wild-type CD44 
accumulates in clusters whereas the mutated receptors redis- 
tribute to a single polar cap. This increased susceptibility to 
ligand-induced modulation may reflect a difference in the 
ability of the wild-type and mutant forms of CD44 to as- 
sociate with other proteins,  including components of the 
cytoskeleton. Phosphorylation of the cytoplasmic domain of 
CD44 may mediate these changes directly or indirectly by 
regulating the association of CD44 with the cytoskeleton. 
The latter is an intriguing possibility since we previously ob- 
served an inverse relationship between the phosphorylation 
of CD44 and its association with the cytoskeleton (8). 
Our results suggest that the function of CD44 may be 
subject to regulation by serine kinase and phosphatase activi- 
ties. Our finding that mutation of either serine 325 or 327 
expressed in T cells completely, or nearly completely, abol- 
ishes phosphorylation of CD44,  although somewhat sur- 
prising,  has been found to be the case in other cell types, 
including epithelial cells (15) and COS7 cells (Camp, tL. L., 
and E. Pur6, unpublished  observation),  as well.  There are 
at least two models that would be consistent with these ob- 
servations. Both serines 325 and 327 could be phosphorylated 
and each required for phosphorylation of either residue, or, 
only one of the two serines may be phosphorylated  and the 
other serine may merely be needed for the kinase to recog- 
nize the substrate. In two-dimensional tryptic peptide maps 
of wild-type recombinant CD44 expressed in COS7 cells and 
of endogenous CD44 isolated from resident and thioglyco- 
lated elicited murine peritoneal macrophages we detected at 
least four distinct phosphopeptides (Put6, E., and K. L. Camp, 
unpublished observation). Although this could result merely 
from incomplete cleavage,  these results are also consistent with 
the possibility that both serines  325 and 327 are phosphorylated 
since there is a predicted tryptic cleavage site located between 
these two serines. It is also interesting to note in this regard 
that neither serine 325 nor 327 is located within a previously 
defined kinase target consensus sequence. 
The data described herein indicate that the potential  for 
phosphorylation of CD44 in T cells is a prerequisite for the 
adhesion function and normal distribution of CD44 on the 
cell surface. However, phosphorylation may not be sufficient 
since unlike in T  cell lymphomas, primary resting T  cells 
do not bind HA although ,050%  of the total cellular pool 
of CD44 in these cells  is phosphorylated (8). However, resting 
primary T cells express lower levels of CD44. Furthermore, 
primary T cells can be induced to bind HA by activation with 
phorbol esters that induce protein kinase C. This results in 
a 5-10-fold increase in the expression of CD44 (7) as well 
as an increase  in the proportion of  CD44 that is phosphorylated 
(Camp, K. L., and E. P. Pur~, unpublished observation). Thus, 
the adhesion function of the receptor may reflect a combina- 
tion of the level of CD44 expressed and the proportion of 
CD44 that is phosphorylated. Other cell type-specific mech- 
anisms may also contribute to the regulation of CD44 medi- 
ated adhesion. 
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